References
- Wang G, Lai FM, Tam LS, et al. Messenger RNA expression of podocyte-associated molecules in urinary sediment of patients with lupus nephritis. J Rheumatol. 2007;34:2358–2364.
- Petermann A, Floege J. Podocyte damage resulting in podocyturia: A potential diagnostic marker to assess glomerular disease activity. Nephron Clin Pract. 2007;106:c61–c66.
- Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol. 2005;16:1733–1741.
- Hara M, Yanagihara T, Kihara I. Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schonlein-Henoch purpura nephritis. Clin J Am Soc Nephrol. 2007;2:231–238.
- Skoberne A, Konieczny A, Schiffer M. Glomerular epithelial cells in the urine: What has to be done to make them worthwhile? Am J Physiol Renal Physiol. 2009;296:F230–F241.
- Konieczny A, Ryba M, Wartacz J, Czyzewska-Buczynska A, Hruby Z, Witkiewicz W. Podocytes in urine, a novel biomarker of preeclampsia? Adv Clin Exp Med. 2013;22:145–149.
- Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol. 2003;285:F40–F48.
- Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–1277.
- Austin HA III, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med. 1983;75:382–391.
- Solorzano G. Marcadores de atividade lúpica. 1 ed. São Paulo: Sarvier; 2008:116–120.
- Petermann AT, Krofft R, Blonski M, et al. Podocytes that detach in experimental membranous nephropathy are viable. Kidney Int. 2003;64:1222–1231.
- Petermann AT, Pippin J, Krofft R, et al. Viable podocytes detach in experimental diabetic nephropathy: Potential mechanism underlying glomerulosclerosis. Nephron Exp Nephrol. 2004;98:e114–e123.
- Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy. Diabetes. 2005;54:1626–1634.
- Lemley KV, Lafayette RA, Safai M, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int. 2002;61:1475–1485.
- Achenbach J, Mengel M, Tossidou I, et al. Parietal epithelia cells in the urine as a marker of disease activity in glomerular diseases. Nephrol Dial Transplant. 2008;23:3138–3145.
- Garovic VD, Wagner SJ, Turner ST, et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol. 2007;196:320 e1–327.
- White WM, Garrett AT, Craici IM, et al. Persistent urinary podocyte loss following preeclampsia may reflect subclinical renal injury. PloS One. 2014;9:e92693
- Jefferson JA, Alpers CE, Shankland SJ. Podocyte biology for the bedside. Am J Kidney Dis. 2011;58:835–845.
- Aita K, Etoh M, Hamada H, et al. Acute and transient podocyte loss and proteinuria in preeclampsia. Nephron Clin Pract. 2009;112:c65–c70.
- Sabino AR, Teixeira Vde P, Nishida SK, Sass N, Mansur JB, Kirsztajn GM. Detection of podocyturia in patients with lupus nephritis. J Bras Nefrol. 2013;35:252–258.
- Yee CS, Isenberg DA, Prabu A, et al. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis. 2008;67:873–876.
- Reyes-Thomas J, Blanco I, Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol. 2011;40:138–150.
- Dall’Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011;63:351–357.
- Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65:2154–2160.
- Rodrigues PG, Bringhenti RN, do Nascimento JF, et al. Expression patterns of podocyte-associated mRNAs in patients with proliferative or non-proliferative glomerulopathies. Int J Clin Exp Pathol. 2014;7:2185–2198.
- Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant. 2002;17:798–802.
- Nakamura T, Ushiyama C, Shimada N, et al. Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Diabetes Care. 2000;23:1168–1171.